Pharmacological action – antioxidant, immunomodulatory, antiviral.
It is an inducer of endogenous interferon, which explains one of the mechanisms of specific antiviral action. It has a radioprotective effect, regulates the water-salt balance, stimulates the processes of corneal regeneration, does not have a teratogenic, mutagenic, embryotoxic effect.
When administered locally, para-aminobenzoic acid is rapidly absorbed and exhibits a therapeutic effect.
When administered topically, para-aminobenzoic acid is rapidly absorbed and exhibits a therapeutic effect.
- Viral conjunctivitis, keratoconjunctivitis, keratouveitis caused by Herpes simplex, Herpes zoster, adenovirus,
- keratopathy of infectious, post-traumatic and postoperative genesis,
- degenerative diseases of the retina and cornea,
- burns and eye injuries,
- discomfort associated with eye strain and fatigue, incl. when wearing contact lenses.
Eye drops 0.007% transparent, colorless.
|para-aminobenzoic acid||70 mcg|
water d / i.
Application during pregnancy and lactation
To date, there are no data from clinical trials regarding the use of the drug during pregnancy, lactation, as well as in children. However, the drug can be used if the intended benefit outweighs the potential risk.
Hypersensitivity to drug components.
Rarely conjunctival hyperemia, local allergic reactions.
In combination with modified nucleosides (acyclovir, ganciclovir, fludarabine phosphate, etc.) and antibiotics, the therapeutic effect is enhanced. Do not use simultaneously with sulfa drugs (albucid), with Enkad when used topically.
How to take, course and dosage
Topically: instilled into the conjunctival sac, 1-2 drops 3-8 times a day.
After clinical recovery, continue instillation of 2 drops 3 times a day for 7 days.
In case of accidental ingestion of the drug Aktipol, there is no risk of developing unwanted side effects.
Do not prescribe Aktipol simultaneously with sulfa drugs for topical use.